

## Levomepromazine

<b>Form</b>	25mg per 1mL ampoule
<b>Reconstitution</b>	Already in solution
<b>Compatibility &amp; Stability</b>	Sodium Chloride 0.9%
<b>Administration</b>	<p>The solution should be clear and colourless. Inspect visually for particulate matter or discoloration prior to administration and discard if present.</p> <p><b><u>IV Injection</u></b> Dilute 1mL injection with an equal volume of sodium chloride 0.9% and give slowly over 3 - 5 minutes.</p> <p><b><u>IM Injection</u></b> No dilution required.</p> <p><b><u>SC Injection</u></b> Give required dose by sc injection</p> <p><b><u>Continuous SC Injection</u></b> Required dose should be diluted with sodium chloride 0.9% to the largest practical volume.</p>
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>• Administration via syringe driver is unlicensed and may increase the administration risk rating. To mitigate these risks:           <ul style="list-style-type: none"> <li>○ Contact the Pharmacy Department or Palliative care team for further guidance.</li> <li>○ Consult the Palliative Care Formulary accessible on <a href="http://www.medicinescomplete.com">www.medicinescomplete.com</a> or the Syringe Driver Survey Database (SDSD) (available after registration on <a href="http://www.palliativedrugs.com">www.palliativedrugs.com</a>) for <a href="#">guidance on syringe driver compatibility</a>.</li> </ul> </li> <li>• CSCI syringes and lines must be protected from light to prevent degradation of levomepromazine and must be discarded if a yellow/pink/purple colour occurs.</li> </ul>

**Information provided relates to Nozinan<sup>®</sup> manufactured by Sanofi.**